What is the acute management for an adult presenting with an acute middle cerebral artery ischemic infarct?

Acute Management of Middle Cerebral Artery Ischemic Infarct

For an adult presenting with acute MCA ischemic infarct, immediately administer IV alteplase (0.9 mg/kg, maximum 90 mg) if the patient presents within 4.5 hours of symptom onset or last known well, followed by evaluation for mechanical thrombectomy with stent retrievers for large vessel occlusion. 1

Immediate Reperfusion Therapy

IV Thrombolysis (First-Line for Eligible Patients)

• Administer IV alteplase 0.9 mg/kg (maximum 90 mg) over 60 minutes, with 10% given as bolus over 1 minute for patients within 3 hours of symptom onset or last known well 1
• Extended window (3-4.5 hours): IV alteplase remains recommended for selected patients who can be treated within this timeframe 1
• Do not delay treatment to pursue additional diagnostic studies when eligibility criteria are met 1
• Treatment eligibility should be determined using established criteria, with physicians reviewing contraindications systematically 1

Mechanical Thrombectomy

• Mechanical thrombectomy with stent retrievers is recommended over intra-arterial thrombolysis as first-line endovascular therapy 1
• For patients with large-core infarcts, recent evidence from multiple trials (RESCUE-Japan LIMIT, ANGEL-ASPECT, SELECT2, TESLA, TENSION, LASTE) supports endovascular treatment even in extended time windows up to 24 hours from last known well 1
• Aspirin should not substitute for IV alteplase or mechanical thrombectomy in otherwise eligible patients 1

Post-Thrombolysis Monitoring Protocol

Intensive Monitoring Requirements

• Admit to intensive care or stroke unit for close monitoring 1
• Blood pressure and neurological assessments:
  • Every 15 minutes during and for 2 hours after IV alteplase infusion
  • Every 30 minutes for the next 6 hours
  • Hourly until 24 hours after treatment 1
• Maintain blood pressure ≤180/105 mm Hg using antihypertensive medications as needed 1
• If severe headache, acute hypertension, nausea, vomiting, or neurological worsening occurs: discontinue alteplase infusion immediately and obtain emergency head CT 1

Delayed Interventions

• Delay placement of nasogastric tubes, indwelling bladder catheters, or intra-arterial pressure catheters if the patient can be safely managed without them 1
• Obtain follow-up CT or MRI at 24 hours before starting anticoagulants or antiplatelet agents 1

Antiplatelet Therapy

• Administer aspirin 160-300 mg within 24-48 hours of stroke onset 1
• For patients receiving IV alteplase: delay aspirin until 24 hours post-thrombolysis, though earlier administration may be considered for compelling concomitant conditions 1
• For minor strokes: dual antiplatelet therapy (aspirin plus clopidogrel) for 21 days initiated within 24 hours can be beneficial for secondary prevention up to 90 days 1
• Rectal or nasogastric administration is appropriate for patients unable to swallow 1

Management of Symptomatic Intracranial Hemorrhage

If hemorrhagic transformation occurs within 24 hours of alteplase:

• Stop alteplase infusion immediately 1
• Obtain CBC, PT/INR, aPTT, fibrinogen level, type and cross-match 1
• Emergent nonenhanced head CT 1
• Administer cryoprecipitate 10 units over 10-30 minutes; give additional dose if fibrinogen <200 mg/dL 1
• Consider tranexamic acid 1000 mg IV over 10 minutes OR ε-aminocaproic acid 4-5 g over 1 hour 1
• Obtain urgent hematology and neurosurgery consultations 1

Supportive Care Measures

Blood Glucose Management

• Treat hyperglycemia to achieve blood glucose 140-180 mg/dL during the first 24 hours, as persistent hyperglycemia is associated with worse outcomes 1
• Treat hypoglycemia (blood glucose <60 mg/dL) immediately 1

Temperature Control

• Avoid hyperthermia: peak temperature >39°C in the first 24 hours is associated with increased in-hospital mortality 1
• Induced hypothermia should only be offered in the context of clinical trials 1

Surgical Decompression for Malignant MCA Infarction

Indications for Decompressive Hemicraniectomy

• Consider decompressive hemicraniectomy for malignant MCA infarction with massive brain edema and herniation risk, as it reduces mortality from 80% to 32-44% 2, 3
• Surgery is most effective when performed early, ideally within 48 hours of symptom onset before critical ICP elevation (>30 mm Hg) occurs 3
• Age is the most significant prognostic factor: patients under 60 years have better functional outcomes, though surgery can be considered in older patients on an individual basis 4

Important Caveats

• While decompressive surgery significantly reduces mortality, morbidity remains high, particularly in elderly patients 2
• Approximately 66% of surgically treated survivors achieve independence with mild-to-moderate disability 3
• Patients and caregivers report higher satisfaction with quality of life post-surgery than healthcare professionals anticipate, highlighting the importance of discussing realistic expectations 2
• Patients with infarctions extending beyond MCA territory (involving ACA/PCA) may require secondary necrosectomy but have comparable recovery potential to isolated MCA infarcts 4

Critical Pitfalls to Avoid

• Do not withhold IV alteplase to pursue additional imaging when eligibility criteria are met and treatment window is closing 1
• Do not use aspirin as a substitute for reperfusion therapy in eligible patients 1
• Do not delay mechanical thrombectomy based solely on large infarct core size, as recent evidence supports benefit even in large-core strokes 1
• Do not miss malignant MCA infarction: recognize clinical and CT criteria early to enable timely surgical consultation 3